Belite Bio Presents 18-Month Interim Results from P-II Study (LBS-008-CT02) of Tinlarebant for Stargardt Disease at ARVO 2023
Shots:
- The 18mos. results from an ongoing 2yr. P-II study (LBS-008-CT02) evaluating Tinlarebant in adolescent patients with STGD1
- The results from fundus autofluorescence (FAF) imaging showed that ~60% of patients demonstrated no incident atrophic retinal lesions, mean visual acuity was stabilized in the study cohort, 9 out of 12 patients experienced mild xanthopsia/chromatopsia and delayed dark adaptation & 1 out of 12 patients experienced night vision impairment
- The therapy was safe & well tolerated, no clinical changes in retinal thickness were seen @18mos. The company is currently enrolling patients in a 2yr. P-III study (DRAGON) of Tinlarebant for STGD1 & plans to begin enrolling patients in a 2yr. P-III study (PHOENIX) for GA in mid-2023
Ref: Globenewswire | Image: Belite Bio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
